Seres Therapeutics (NASDAQ:MCRB) Lowered to “Sell” Rating by StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other brokerages also recently weighed in on MCRB. JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Seres Therapeutics has an average rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Price Performance

Shares of NASDAQ MCRB opened at $0.84 on Friday. The company has a market cap of $144.15 million, a PE ratio of -3.67 and a beta of 2.13. The stock has a fifty day moving average price of $0.83 and a 200 day moving average price of $0.91. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $1.53.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its position in Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after purchasing an additional 255,014 shares during the last quarter. FMR LLC lifted its stake in Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after buying an additional 140,096 shares in the last quarter. State Street Corp grew its holdings in Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 43,700 shares during the last quarter. Finally, Providence Wealth Advisors LLC increased its position in Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after buying an additional 22,250 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.